A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumor

Interventions

DRUG

RC108

RC108 for injection is a novel antibody-drug conjugate, with a c-Met-targeting antibody and a microtube inhibitor.

Trial Locations (4)

National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

Hunan Cancer Hospital, Changsha

The First Hospital of Jilin University, Changchun

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY

NCT04617314 - A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors | Biotech Hunter | Biotech Hunter